1. Home
  2. ZCMD vs IMNN Comparison

ZCMD vs IMNN Comparison

Compare ZCMD & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zhongchao Inc.

ZCMD

Zhongchao Inc.

SELL

Current Price

$1.39

Market Cap

7.1M

Sector

Real Estate

ML Signal

SELL

Logo Imunon Inc.

IMNN

Imunon Inc.

HOLD

Current Price

$1.06

Market Cap

7.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZCMD
IMNN
Founded
2012
1982
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1M
7.9M
IPO Year
2019
2000

Fundamental Metrics

Financial Performance
Metric
ZCMD
IMNN
Price
$1.39
$1.06
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $17.00
AVG Volume (30 Days)
★ 237.7K
111.1K
Earning Date
12-22-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.02
$0.96
52 Week High
$11.96
$5.25

Technical Indicators

Market Signals
Indicator
ZCMD
IMNN
Relative Strength Index (RSI) 53.96 26.46
Support Level $1.31 N/A
Resistance Level $1.69 $1.59
Average True Range (ATR) 0.12 0.10
MACD -0.00 -0.02
Stochastic Oscillator 46.36 14.58

Price Performance

Historical Comparison
ZCMD
IMNN

About ZCMD Zhongchao Inc.

ZHONGCHAO Inc is an offshore holding company. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provides healthcare information, education, and training services to healthcare professionals under its MDMOOC brand. It also provides focused patient management services through the Zhongxun IT system and WeChat mini program, and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.

Share on Social Networks: